Daniel Margolis is a partner in the firm’s Intellectual Property Litigation practice. Clients rely upon the combination of legal and scientific expertise he brings to his practice, which focuses on patent litigation and strategic counseling, with a particular emphasis on pharmaceuticals and chemical technologies. Dr. Margolis’ expertise allows him to address complex issues for his clients with respect to legal and overall business strategies.

Dr. Margolis has litigated patent disputes extensively on behalf of both plaintiffs and defendants in federal courts, before the Patent Trial and Appeal Board, and in the International Trade Commission. His cases predominantly involve highly complex chemical technologies, whether in the context of Hatch-Waxman cases or those involving traditional allegations of infringement of chemical patents.





Representative matters include:

  • In re: Copaxone 775 Patent Litigation (D. Del.): Representing Teva in patent infringement litigation against multiple generic defendants involving patents directed to a process for manufacturing glatiramer acetate (Copaxone®).
  • Impax Labs., Inc. v. Actavis Labs. FL, Inc. (D.N.J): Represented Actavis in a patent infringement litigation involving formulations of levodopa and carbidopa and the treatment of Parkinson’s disease.
  • Senju Pharmaceutical Co., Ltd., et al. v. Lupin, Ltd., et al. (D.N.J.). Represented Lupin in a patent infringement litigation concerning Lupin’s generic equivalent to Bausch & Lomb’s Prolensa®, an anti-inflammatory ophthalmic drug.
  • Cubist Pharmaceuticals, Inc. v. Fresenius Kabi USA, LLC (D. Del.): Represented Fresenius in a patent litigation concerning Fresenius’s generic equivalent to Cubist’s lipopeptide antibiotic product, Cubicin®.
  • In the Matter of Certain Omega-3 Extracts from Marine or Aquatic Biomass and Products Containing the Same (ITC). Represented Enzymotec in a United States International Trade Commission investigation concerning alleged infringement by Enzymotec’s krill oil supplements. The representation also involved an inter partes review before the Patent Trial and Appeal Board in the United States Patent and Trademark Office.
  • Gilead Sciences, Inc., et al. v. Teva Pharmaceuticals USA, Inc., et al. (S.D.N.Y.). Represented Teva in a series of patent infringement litigations concerning Teva’s generic equivalents to the anti-HIV drugs, Viread®, Truvada®, and Atripla®.
  • In re Gabapentin Patent Litigation (D.N.J.). Represented Teva in a patent infringement litigation concerning Teva’s generic equivalent to Pfizer’s Neurontin®, an anti-eplileptic drug.
  • AstraZeneca AB, et al. v. IVAX Corp., et al (D.N.J.). Represented Teva in a patent infringement litigation concerning Teva’s generic equivalent to AstraZeneca’s Nexium®, a drug for treating gastroesophageal reflux disease.
Professional Experience

Prior to joining Goodwin, Dr. Margolis was an associate in the New York office of Kenyon & Kenyon.


Dr. Margolis was selected to the Super Lawyers New York Metro Rising Stars list in 2013-2017. While in law school, he served as casebook research and writing editor for the Moot Court Board.

In The News









J.D., 2006
New York University School of Law
Ph.D., Chemical Engineering, 2003
Carnegie Mellon University
B.S., Chemical Engineering, 1998
Rutgers University, College of Engineering

(high honors, Tau Beta Pi)



New York


U.S. District Court for the Southern District of New York
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique